The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Early diagnosis, treatment, and prevention of a vaso‐occlusive crisis (VOC) are critical to the management of patients with sickle cell disease. It is essential to differentiate between VOC‐associated pain and chronic pain, hyperalgesia, neuropathy, and neuropathic pain. The pathophysiology of VOCs includes polymerization of abnormal sickle hemoglobin, inflammation, and adhesion. Hydroxyurea, L‐glutamine, crizanlizumab, and voxelotor have been approved by the US Food and Drug Administration for reducing the frequency of VOCs; the European Medicines Agency has approved only hydroxyurea. Other novel treatments are in late‐stage clinical development in both the United States and the European Union. The development of agents for prevention and treatment of VOCs should be driven by our understanding of its pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 3×
“levels of fetal hemoglobin may be protective against VOC and other pathological consequences of SCD due to its interfering with polymerization of sickle hemoglobin during the sickling process (56,57), and are also inversely related to mortality (4).”
BackgroundEffect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 1×
“Hydroxyurea has been shown to increase levels of fetal hemoglobin, which appears to be protective against VOC (73,74).”
BackgroundCauses and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Vichinsky, E. P., Neumayr, L. D., Earles, A. N., Williams, R., Lennette, E. T., Dean, D., Nickerson, B., Orringer, E., McKie, V., Bellevue, R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422502 · Cited by 1,234 · cited 1×
“However, pain usually precedes onset of ACS, with ACS occurring about 3 days after the onset of VOC (9).”
BackgroundSelf-citationCrizanlizumab for the prevention of pain crises in sickle cell disease.
Ataga, K. I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., Guthrie, T. H., Knight-Madden, J., Alvarez, O. A., Gordeuk, V. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611770 · Cited by 914
Selectins: initiators of leucocyte adhesion and signalling at the vascular wall
McEver, R. P. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv154 · Cited by 575
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Manwani, D., & Frenette, P. S. (2013) · Blood · doi:10.1182/blood-2013-05-498311 · Cited by 428
Zhang, D., Xu, C., Manwani, D., & Frenette, P. S. (2016) · Blood · doi:10.1182/blood-2015-09-618538 · Cited by 413
Martyn, G. E., Wienert, B., Yang, L., Shah, M., Norton, L. J., Burdach, J., Kurita, R., Nakamura, Y., Pearson, R. C. M., Funnell, A. P. W., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0085-0 · Cited by 300 · cited 2×
“Genetic predictors Single nucleotide polymorphisms: +191 and +292 in galectin-3 gene (LGALS3) (71) Mutations in the γ-globin gene promoter that disrupt binding of major fetal globin repressors (72)”
BackgroundTelen, M. J., Wun, T., McCavit, T. L., De Castro, L. M., Krishnamurti, L., Lanzkron, S., Hsu, L. L., Smith, W. R., Rhee, S., Magnani, J. L., et al. (2015) · Blood · doi:10.1182/blood-2014-06-583351 · Cited by 211
Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin
Metcalf, B., Chuang, C., Dufu, K., Patel, M. P., Silva-Garcia, A., Johnson, C., Lu, Q., Partridge, J. R., Patskovska, L., Patskovsky, Y., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00491 · Cited by 203
Metadata
- Authors
- Darbari, D. S., Sheehan, V. A., & Ballas, S. K.
- Venue
- European Journal of Haematology
- Publisher
- Wiley
- Published
- 2020-05-19
- Volume
- 105
- Issue
- 3
- Pages
- 237-246
- ISSN
- 0902-4441 (ISSN-L)
- 1600-0609
- OpenAlex
- W3016435988
- Cited by
- 243
- References
- 13
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. https://app.cochat.ai/papers/10.1111/ejh.13430
- The paper
- Darbari, D. S., Sheehan, V. A., & Ballas, S. K. (2020). The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. European Journal of Haematology. https://doi.org/10.1111/ejh.13430
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.